Abstract: A class of compounds containing a tricyclic heteroaryl group is provided. Specifically, a compound of the structure represented by the following formula (I) (each group is as defined in the specification), a pharmaceutical composition containing the compound of the formula (I), and their isotope derivatives, chiral isomers, allosteries, different salts, prodrugs, preparations, etc, are provided. It can effectively inhibit protein kinases (such as EGFR, FAK, SYK, FLT-3, Axl, CDK, JAK, etc.), thereby treating various tumors, non-alcoholic liver disease (NASH), pulmonary fibrosis (IPF), and related variety of diseases.
Type:
Application
Filed:
July 23, 2020
Publication date:
November 12, 2020
Inventors:
Hancheng ZHANG, Shifeng LIU, Xiangyang YE
Abstract: A compound of formula I: or a pharmaceutically acceptable salt thereof, wherein: W is O, N—H, N—(C1-C10 alkyl) or S; each X is independently CH or N; R1 is a 5 to 7-membered saturated or unsaturated, optionally substituted heterocycle containing at least 1 heteroatom selected from N or O; R2 is LY; each L is a direct bond, C1-C10 alkylene, C2-C10 alkenylene or C2-C10 alkynylene; Y is an optionally substituted fused, bridged or spirocyclic non-aromatic 5-12 membered heterocycle containing up to 4 heteroatoms selected from N or O; and each R3 is independently H, C1-C10 alkyl, halogen, fluoro C1-C10 alkyl, O—C1-C10 alkyl, NH—C1-C10 alkyl, S—C1-C10 alkyl, O-fluoro C1-C10 alkyl, NH-acyl, NH—C(O)—NH—C1-C10 alkyl, C(O)—NH—C1-C10 alkyl, aryl or heteroaryl, are useful as inhibitors of the class IA phosphoinositide 3-kinase enzyme, PI3K-p110?, and therefore have potential utility in the therapy of cancer, immune and inflammatory diseases.
Type:
Application
Filed:
November 8, 2019
Publication date:
November 12, 2020
Inventors:
Stephen Joseph Shuttleworth, Alexander Richard Liam Cecil, Franck Alexandre Silva
Abstract: The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV replication cycle, compositions comprising such compounds, methods for inhibiting HBV viral replication, methods for treating or preventing HBV infection, and processes and intermediates for making the compounds.
Abstract: A modular tetrazine platform, can be used as diagnostic, theragnostic agent and/or medicinal product. An inverse electron demand Diels-Alder reaction can be used for synthesizing bifunctionalized tetrazines, which can be obtained from monofunctionalised tetrazines.
Type:
Application
Filed:
March 23, 2018
Publication date:
November 12, 2020
Inventors:
Victor Goncalves, Franck Denat, Claire Bernhard, Coline Canovas
Abstract: ?-amino boronic acid derivatives are useful for inhibiting the activity of immunoproteasome (LMP7) and for the treatment and/or prevention of medical conditions affected by immunoproteasome activity such as inflammatory and autoimmune diseases, neurodegenerative diseases, proliferative diseases and cancer.
Type:
Application
Filed:
August 21, 2018
Publication date:
November 12, 2020
Applicant:
Merck Patent GmbH
Inventors:
Markus Klein, Oliver Schadt, Christina Esdar
Abstract: A method of producing a polyether polyol includes reacting a low molecular weight initiator with ethylene oxide in the presence of a polymerization catalyst, and the low molecular weight initiator has a nominal hydroxyl functionality at least 2. The polymerization catalyst is a Lewis acid catalyst having the general formula M(R1)1(R2)1(R3)1(R4)0 or 1, whereas M is boron, aluminum, indium, bismuth or erbium, R1, R2, R3, and R4 are each independent, R1 includes a fluoroalkyl-substituted phenyl group, R2 incudes a fluoroalkyl-substituted phenyl group or a fluoro/chloro-substituted phenyl group, R3 includes a fluoroalkyl-substituted phenyl group or a fluoro/chloro-substituted phenyl group, and optional R4 includes a functional group or functional polymer group, R1 being different from at least one of R2 and R3.
Type:
Application
Filed:
September 14, 2018
Publication date:
November 12, 2020
Inventors:
Arjun Raghuraman, William H. Heath, Sukrit Mukhopadhyay, Heather A. Spinney, David R. Wilson, Jeffery Goodwin
Abstract: The present invention relates to compounds and methods useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.
Type:
Application
Filed:
February 4, 2020
Publication date:
November 12, 2020
Inventors:
Mark E. GURNEY, Timothy J. HAGEN, Xuesheng MO, A. Samuel VELLEKOOP, Donna L. ROMERO, Robert CAMPBELL, Joel R. WALKER, Lei ZHU
Abstract: Coordinative alignment uses x-ray diffraction to precisely and unambiguously determine the structure of molecules bound or crystallized within chiral metal organic frameworks.
Type:
Application
Filed:
July 30, 2020
Publication date:
November 12, 2020
Applicant:
The Regents of the University of California
Inventors:
Seungkyu Lee, Eugene A. Kapustin, Omar M. Yaghi
Abstract: A method and composition for producing a porous low k dielectric film via chemical vapor deposition is provided. In one aspect, the method comprises the steps of: providing a substrate within a reaction chamber; introducing into the reaction chamber gaseous reagents including at least one structure-forming precursor comprising a alkoxysilacyclic or acyloxysilacyclic compound with or without a porogen; applying energy to the gaseous reagents in the reaction chamber to induce reaction of the gaseous reagents to deposit a preliminary film on the substrate, wherein the preliminary film contains the porogen, and the preliminary film is deposited; and removing from the preliminary film at least a portion of the porogen contained therein and provide the film with pores and a dielectric constant of 3.2 or less. In certain embodiments, the structure-forming precursor further comprises a hardening additive.
Type:
Application
Filed:
August 29, 2018
Publication date:
November 12, 2020
Inventors:
Robert Gordon Ridgeway, Raymond Nicholas Vrtis, Xinjian Lei, Jennifer Lynn Anne Achtyl, William Robert Entley
Abstract: The present invention relates to a process for preparing a mixture M1 of enol phosphate isomers devoid of (E,E) isomer and comprising at least 98% of (E,Z) isomer, at least 0.1% of (Z,Z) isomer and at least 0.1% of (Z,E) isomer, comprising bringing a mixture of isomers of said enol phosphate comprising a detectable amount of (E,E) isomer into contact with a hydrolysable dienophile in an organic solvent, followed by base hydrolysis of the medium obtained and elimination of the adduct formed, in order to obtain the mixture M1 devoid of (E,E) isomer.
Type:
Application
Filed:
March 9, 2018
Publication date:
November 12, 2020
Applicants:
Universite De Bordeaux, Institut Polytechnique De Bordeaux, Centre National de la Recherche Scientifique (CNRS)
Abstract: The present invention relates to a real-time fluorescence imaging sensor for measuring glutathione in cell organelles and a method for fabricating the same. More specifically, the present invention relates to a novel compound for measuring glutathione in cell organelles, a method for preparing the novel compound, a real-time fluorescence imaging sensor for measuring glutathione in cell organelles, which comprises the novel compound, a method for fabricating the imaging sensor, and a method of measuring glutathione in cell organelles by use of the imaging sensor. When the composition comprising the compound according to the present invention is used, it can measure the antioxidant activity of the organelle mitochondria or Golgi apparatus in living cells, particularly stem cells, and can screen highly active stem cells based on the results obtained by measuring the antioxidant activity of the cell organelle.
Type:
Application
Filed:
August 23, 2018
Publication date:
November 12, 2020
Inventors:
Heun Soo Kang, Hye Mi Kim, Ji Eun Song, Myoung Jin Kim, Ki Hang Choi
Abstract: Provided is a process for preparation of a compound of Formula 1 where, ring Y and ring Z are each independently a 5-membered or 6-membered carbocyclic or heterocyclic ring; Z1 and Z2 are each independently C or N; each RY and RZ independently represents mono to the maximum possible number of substitutions, or no substitution; x=1, 2, or 3; y=0, 1, or 2; and x+y=3.
Abstract: Disclosed is an organic light-emitting material including a 3-deuterium-substituted isoquinoline ligand. The organic light-emitting material is a metal complex including a 3-deuterium-substituted isoquinoline ligand and an acetylacetonate ligand, which can be used as a light-emitting material in a light-emitting layer of an organic electroluminescent device. These novel complexes can effectively prolong device lifetime. Further disclosed is an electroluminescent device including the metal complex and a compound formulation.
Type:
Application
Filed:
May 8, 2020
Publication date:
November 12, 2020
Inventors:
Qi ZHANG, Cuifang ZHANG, Chi Yuen Raymond KWONG, Chuanjun XIA
Abstract: A compound including a first ligand LA of is disclosed. In the structure of Formula I, one of L1 and L2 is C, and the other is N; Y1 to Y14 are each C or N; at least two adjacent Y7, Y8, Y9, and Y10 are carbon atoms that are fused to a structure of Z1 and Z2 are each O, S, Se, NR, CRR?, or SiRR?; and each R, R?, RA, RB, RC, and RD is hydrogen or a substituent; and any two substituents may be joined or fused together to form a ring. In the compound, LA is complexed to a metal M by L1 and L2, and M has an atomic weight greater than 40. Organic light emitting devices and consumer products containing the compounds are also disclosed.
Type:
Application
Filed:
July 30, 2020
Publication date:
November 12, 2020
Applicant:
UNIVERSAL DISPLAY CORPORATION
Inventors:
Zhiqiang LI, Jui-Yi TSAI, Alexey Borisovch DYATKIN, Chun LIN
Abstract: An organometallic compound represented by Formula 1, an organic light-emitting device including the organometallic compound, and a diagnostic composition including the organometallic compound: M11(L11)n11(L12)n12??Formula 1 wherein, in Formula 1, M11 is a first-row transition metal, a second-row transition metal, or a third-row transition metal, L11 is a ligand represented by Formula 1-1, L12 is a monodentate ligand or a bidentate ligand, n11 is 1, and n12 is 0, 1, or 2: wherein, in Formula 1-1, Y11, A11, T11 k11, k12, k13, b11, E11 to E13 and R11 to R17 are described in the specification, and *1 to *4 each independently indicate a binding site to M11.
Type:
Application
Filed:
January 16, 2020
Publication date:
November 12, 2020
Inventors:
Hyejin Bae, Wataru SOTOYAMA, Sangmo Kim, Wook Kim, Jongsoo Kim, Joonghyuk Kim, Minsik Min, Jhunmo Son, Hasup Lee, Yongsik Jung
Abstract: The present disclosure is in relation to the field of nanotechnology and cancer therapeutics. In particular, the present disclosure relates to platinum based compounds comprising platinum moiety, linker moiety and lipid moiety and corresponding nanoparticles thereof. The disclosure further relates to synthesis of said platinum based compounds, nanoparticles and compositions comprising said platinum based compounds/nanoparticles. The disclosure also relates to methods of managing cancer by employing aforesaid carbene compounds, platinum based compounds, nanoparticles and compositions thereof.
Abstract: Compositions and compounds of nucleoside phosphoramidites and modified oligonucleotides, each comprising one or more charge-neutralizing moieties according to the formula V The nucleoside phosphoramidites permit facile attachment of the neutralizing moieties on the backbones of the modified oligonucleotides. The modified oligonucleotides can be used as therapeutic agents (i.e., oligotherapeutics) for the treatment of cancer, autoimmune disorders, genetic diseases, infectious diseases, neurological diseases, inflammatory diseases, metabolic diseases and others.
Abstract: Provided herein is a compound of Formula (I-I), or a pharmaceutically acceptable salt thereof, wherein the variables are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I-I), and methods of using the compounds, e.g. in the treatment of CNS-related disorders.
Type:
Application
Filed:
January 11, 2019
Publication date:
November 12, 2020
Inventors:
Albert Jean Robichaud, Francesco G. Salituro, Maria Jesus Blanco-Pillado, Daniel La, Boyd L. Harrison
Abstract: The invention provides methods and systems for production of recombinant protein, and particularly, for production of recombinant protein from inclusion bodies. For example, in one aspect, the method comprises providing a protein preparation comprising inclusion bodies, preparing an inclusion body dispersion, and exposing the protein preparation to high pressure in a pressure vessel, to disaggregate and refold the inclusion body protein.
Abstract: The present invention relates to a stationary phase for the purification of polyclonal anti-Giardia IgG and IgY antibodies, as well as a method for purifying polyclonal anti-Giardia IgG and IgY antibodies by affinity chromatography. The invention also relates to the polyclonal anti-Giardia IgG and IgY antibodies purified by affinity chromatography, which specifically bind to the antigenic proteins CWP1, alpha-giardin 7.3 and kinesin 3. In an additional aspect, the invention relates to a method for diagnosing giardiasis by detection of Giardia in a specific sample, and a kit for diagnosing giardiasis in biological and environmental samples.
Type:
Application
Filed:
December 18, 2017
Publication date:
November 12, 2020
Applicant:
Instituto Nacional de Salud
Inventors:
Ángela Liliana ALBARRACÍN CÁRDENAS, Adriana ARÉVALO JAMAICA, Sofía DUQUE BELTRÁN, Fabio Leonardo QUINTERO VARGAS, Cesar Augusto RAMÍREZ SEGURA
Abstract: Peptide compositions and methods for inhibiting neovascularization or development of pathological or aberrant blood vessels in human or other animal subjects.
Type:
Application
Filed:
May 25, 2020
Publication date:
November 12, 2020
Inventors:
John Y Park, Hampar L. Karageozian, Vicken H. Karageozian
Abstract: Described are dual mass-spectrometry-cleavable cross-linkers that can be cleaved selectively using two differential tandem mass-spectrometric techniques such as collision induced dissociation (CID) or electron transfer dissociation (ETD), i.e., a dual cleavable crosslinking technology (DUCCT) cross-linker. When used to cross-link a macromolecule, such as a peptide, MS/MS fragmentation produces two signature complementary mass spectra of same cross-linked peptides, the analysis of which gives rise to high confidence in characterizing the structures of the cross-linked macromolecules as well as sites of interactions. Also described, are methods of making and using DUCCT cross-linkers.
Abstract: Compounds for use in synthesis of peptidomimetic agents; synthesis of peptidomimetic agents; peptidomimetic diagnostic and therapeutic agents; and uses of the compounds and peptidomimetic agents in drug discovery, diagnosis, prevention and treatment of diseases are described.
Type:
Application
Filed:
May 8, 2020
Publication date:
November 12, 2020
Applicant:
THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH
Abstract: The present invention relates to a method for activating helper T cells, which includes the step of activating helper T cells by adding a WT1 peptide to antigen presenting cells, wherein the WT1 peptide has the ability to bind to any MHC class II molecule of an HLA-DRB1*0101 molecule, an HLA-DRB1*0401 molecule, an HLA-DRB1*0403 molecule, an HLA-DRB1*0406 molecule, an HLA-DRB1*0803 molecule, an HLA-DRB1*0901 molecule, an HLA-DRB1*1101 molecule, an HLA-DRB3*0202 molecule, an HLA-DRB4*0101 molecule, an HLA-DPB1*0201 molecule or an HLA-DPB1*0301 molecule, and the like.
Type:
Application
Filed:
March 31, 2020
Publication date:
November 12, 2020
Applicants:
International Institute of Cancer Immunology, Inc., OTSUKA PHARMACEUTICAL CO., LTD.
Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which bind to OX40. The invention also relates to multimeric binding complexes of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold that are functional agonists of OX40. The invention also includes drug conjugates comprising said peptides and complexes, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands, complexes and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by OX40.
Type:
Application
Filed:
May 11, 2020
Publication date:
November 12, 2020
Inventors:
Tom Li STEPHEN, Kevin MCDONNELL, Nicholas KEEN, Liuhong CHEN, Helen HARRISON, Peter U. PARK, Michael SKYNNER, Harvey CHE
Abstract: The present disclosure describes novel peptides, including peptides that inhibit the proteolytic activity of insulin-degrading enzyme (IDE). Also described are cosmetic and pharmaceutical formulations including these peptides, as well as a treatment method aimed at improving the appearance and/or texture of skin and/or promoting wound healing and a method for treating diabetes. The disclosed peptides and formulations are particularly useful for addressing the problem of impaired wound healing in diabetes.
Abstract: The present invention provides cyclic depsipeptide compounds of formula (I) and compositions comprising the compounds that are effective against parasites that harm animals. The compounds and compositions may be used for combating parasites in or on mammals and birds. The invention also provides for an improved method for eradicating, controlling and preventing parasite infestation in birds and mammals.
Type:
Application
Filed:
July 30, 2020
Publication date:
November 12, 2020
Applicant:
BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
Inventors:
Loic Le Hir de Fallois, Greg Pacofsky, Alan Long, Charles Meng, Hyoung Ik Lee, Cyprian O. Ogbu
Abstract: Producing adenovirus gene therapy vector in producer cells that express or over-express adenoviral polypeptide IX enables one to produce pIX-deleted adenovirus in suspension cell culture. Using producer cells that express or over-express adenoviral polypeptide IX also increases the yield of adenovirus vector, regardless of whether that adenovirus is pIX-deleted. Using producer cells that express or over-express adenoviral polypeptide IX also improves the resulting vector's transduction kinetics, reducing the number of pfu/target cell required to achieve a given level of transduction/infection, shortening the time the vector requires to transduce or infect a target cell, and shortening the time an infected target cell produces progeny virus.
Type:
Application
Filed:
September 13, 2019
Publication date:
November 12, 2020
Applicant:
Kuopio Center for Gene and Cell Therapy Oy
Inventors:
Vesa TURKKI, Saana LEPOLA, Hanna LESCH, Seppo YLA-HERTTUALA
Abstract: The present invention relates i.a. to a recombinant avian coronavirus spike protein or fragment thereof comprising a mutation at amino acid position 267 to Cysteine. Further, the present invention relates to an immunogenic composition comprising an avian coronavirus with such spike protein.
Type:
Application
Filed:
May 6, 2020
Publication date:
November 12, 2020
Inventors:
Annika KRAEMER-KUEHL, Thomas Min STEPHAN, Hans-Christian PHILIPP
Abstract: Disclosed herein are chimeric fusion proteins comprising a c-Myc inhibitor fused to genetically modified Pseudomonas Aeroginosa Exotoxin A (‘tPE’), said fusion proteins being capable of penetrating a nucleus of a cell and inhibiting c-Myc activity within the nucleus. Also disclosed herein are pharmaceutical compositions comprising chimeric fusion proteins, methods of delivering, methods of preparing, methods of treating and uses of chimeric fusion proteins.
Type:
Application
Filed:
November 29, 2018
Publication date:
November 12, 2020
Inventors:
Frederic Bard, Alexandre Chaumet, Trinda Anne Ting
Abstract: Novel nucleic acid vectors comprising sequences encoding (a) an antigen, (b) a signal peptide, and (c) a heat shock protein, are disclosed, as are methods for using such vectors to induce antigen-specific immune responses and to treat tumors.
Abstract: The present application describes stapled peptide degron chimeras, which act as protein degradation inducing moieties, either by combining a stapled peptide that binds a disease-related protein with a small molecule degron, such as a cereblon- or VHL-binding small molecule as the degron, or a polypeptide sequence degron, such as a Cop1-binding Trib peptide as the degron; or by combining a stapled peptide degron with a peptide, such as a stapled peptide, or a small molecule that binds a disease-related protein. The present application also relates to methods for the targeted degradation of endogenous proteins through the use of stapled peptide degron chimeras which can be utilized in the treatment of proliferative disorders or other conditions whereby elimination of a disease-causing or disease-related protein would have a therapeutic benefit. The present application also provides methods for making compounds of the application and intermediates thereof.
Type:
Application
Filed:
December 14, 2018
Publication date:
November 12, 2020
Inventors:
Loren D. Walensky, Gregory H. Bird, Ann Morgan Cathcart, Rida Mourtada, Henry D. Herce, James E. Bradner
Abstract: The present disclosure is directed to systems and methods for synthesizing a spidroin. In some embodiments, the methods comprise synthesizing a monomer in vivo in a heterologous host, the monomer comprising an N-terminus IntC domain and a C-terminus IntN domain, and post-translationally polymerizing the synthesized monomer via in vitro split-intein mediated polymerization.
Type:
Application
Filed:
December 13, 2019
Publication date:
November 12, 2020
Applicant:
Washington University
Inventors:
Fuzhong Zhang, Christopher H. Bowen, Bin Dai
Abstract: The present disclosure relates to a self-assembled nanostructure of an elastin- and resilin-based block copolypeptide with stimuli responsiveness and resilience for drug delivery, tissue engineering and regenerative medicine, a method for preparing the same and application thereof. The diblock polypeptide reversibly forms a self-assembled micelle structure in response to temperature stimuli and a hydrogel prepared using the triblock polypeptide undergoes reversible sol-gel or gel-sol transition in response to temperature stimuli and exhibits enhanced mechanical strength due to chemical crosslinkages between tyrosine residues. With such superior properties, the diblock/triblock polypeptide of the present disclosure can be used for drug delivery systems, scaffolds for tissue engineering and kits for tissue or organ regeneration.
Type:
Application
Filed:
March 23, 2017
Publication date:
November 12, 2020
Applicant:
Industry-University Cooperation Foundation Hanyang University Erica Campus
Inventors:
Dong Woo LIM, Aamna BASHEER, Jae Sang LEE, Min Jung KANG
Abstract: Methods of treating or inhibiting inflammation in a subject include administering an anti-inflammatory protein to the subject. In some embodiments, the protein has at least 80% sequence identity to the amino acid sequence set forth as SEQ ID NO: 1, SEQ ID NO: 17, or fragments thereof. Isolated polypeptides, nucleic acids, and recombinant vectors including a nucleic acid encoding the anti-inflammatory protein (such as a nucleic acid encoding a protein with at least 80% sequence identity to SEQ ID NO: 1, SEQ ID NO: 17, or fragments thereof) operably linked to a heterologous promoter are also disclosed.
Abstract: The present invention is related to the use of HMGB1 antagonists in the treatment and/or prevention and/or inhibition of acute lung injury in mammals, e.g., humans, and pharmaceutical compositions for the same comprising HMGB1 antagonists, in particular K883, in an effective amount to treat and/or prevent and/or inhibit this condition.
Type:
Application
Filed:
May 8, 2020
Publication date:
November 12, 2020
Applicant:
THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH
Abstract: The present disclosure provides, in part, a method of treating subjects with Duchenne muscular dystrophy (DMD) via gene editing approaches that induce exon deletion(s) to restore the reading frame of the dystrophin gene, thereby restoring dystrophin protein activity. The invention also provides compositions comprising adeno-associated viral vectors, an RNA-guided nucleases, nickases or DNA endonucleases, and guide RNAs for use in the treatment of subjects with DMD, or subjects with other neuromuscular genetic diseases or disorders.
Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of diabetic neuropathy, wherein the pharmaceutical composition comprises, as active ingredients, different types of isoforms of HGF or a polynucleotide encoding the isoforms. The present invention is the first invention demonstrating that diabetic neuropathy can be prevented and treated using different types of isoforms of HGF. According to the present invention, it is possible to very effectively treat diabetic neuropathy.
Abstract: The invention features methods of treatment and diagnosis using NRG-2 polypeptides, nucleic acid molecules, and antibodies. The invention also provides novel NRG-2 polypeptides and nucleic acid molecules.
Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
Abstract: The present invention relates, in part, to agents that bind XCR1 and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the XCR1 binding agents and their use in the treatment of various diseases.
Abstract: The present invention relates to a novel peptide analog of acylated oxyntomodulin and a pharmaceutical composition comprising the same for preventing and treating obesity or overweightness, or diabetes accompanied by obesity and overweightness. The peptides are superior to those of natural oxyntomodulin in dual agonism on GLP-1 and glucagon receptors and longer in vivo half-life. A pharmaceutical composition comprising said peptides is effective in the treatment of metabolic diseases such as obesity and diabetes mellitus.
Type:
Application
Filed:
August 16, 2018
Publication date:
November 12, 2020
Applicant:
DONG-A ST CO., LTD.
Inventors:
Jae-Sung YANG, Kyung-Seok LEE, Yu-Na CHAE, Gye-Rim BAEK, Tae-Hyoung KIM, Ill-Hun JUNG, Chae-Lim RYU, Weon-Bin IM